Tango Therapeutics
TNGX
87 hedge funds and large institutions have $247M invested in Tango Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
13% more funds holding
Funds holding: 77 → 87 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.74% less ownership
Funds ownership: 80.15% → 77.41% (-2.7%)
23% less capital invested
Capital invested by funds: $319M → $247M (-$72.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.11M |
| 2 |
Walleye Capital
New York
|
+$1.73M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.48M |
| 4 |
Goldman Sachs
New York
|
+$829K |
| 5 |
State Street
Boston,
Massachusetts
|
+$556K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$15.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.53M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.12M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.74M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.67M |
TNGX Hedge Fund Activity: Q3 2022 in Review
87 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q3 2022, worth a combined $247M — down 23% from $319M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TNGX positions and 10 closed out — a net gain of 10 holders — while 22 added to existing stakes and 19 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $8.11M. The largest seller was Casdin Capital, exiting entirely with an estimated $15.9M sold.
- 87 institutional investors held Tango Therapeutics (TNGX) as of Q3 2022, up from 77 in Q2 2022.
- Funds reported $247M of Tango Therapeutics stock for Q3 2022, down 23% quarter-over-quarter.
- 20 funds opened new Tango Therapeutics positions in Q3 2022 and 10 closed out, a net change of +10 holders.
- The largest Tango Therapeutics buyer in Q3 2022 was EcoR1 Capital, an estimated $8.11M added.
- The largest Tango Therapeutics seller in Q3 2022 was Casdin Capital, an estimated $15.9M sold.
Based on aggregated 13F filings for Q3 2022.